Emisphere’s eligen technology is the basis of the company’s unique and improved delivery of therapeutic molecules and pharmaceutical compounds.
Michael Novinski, president and CEO of Emisphere, said: “This data demonstrates an exciting potential commercial avenue for our technology that can have a positive impact on the lives of many patients and Emisphere.”